Attached files

file filename
EX-32.1 - EX-32.1 - REATA PHARMACEUTICALS INCreta-ex321_6.htm
EX-31.2 - EX-31.2 - REATA PHARMACEUTICALS INCreta-ex312_14.htm
EX-31.1 - EX-31.1 - REATA PHARMACEUTICALS INCreta-ex311_9.htm
EX-23.1 - EX-23.1 - REATA PHARMACEUTICALS INCreta-ex231_13.htm
EX-21.1 - EX-21.1 - REATA PHARMACEUTICALS INCreta-ex211_298.htm
EX-10.38 - EX-10.38 - REATA PHARMACEUTICALS INCreta-ex1038_1163.htm
EX-10.37 - EX-10.37 - REATA PHARMACEUTICALS INCreta-ex1037_1164.htm
10-K - 10-K - REATA PHARMACEUTICALS INCreta-10k_20201231.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Reata Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Manmeet S. Soni, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 1, 2021

 

By:

 

/s/ Manmeet S. Soni

 

 

 

 

Manmeet S. Soni

 

 

 

 

Chief Operating Officer, Chief Financial Officer, and Executive Vice President

 

 

 

 

(Principal Financial Officer)